Back to Search
Start Over
Efficacy of abiraterone or enzalutamide following docetaxel chemotherapy in the hormone-sensitive setting
- Source :
- Journal of Clinical Oncology. 36:e17022-e17022
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- e17022Background: Docetaxel is now a standard of care for the treatment of newly diagnosed castrate-sensitive metastatic prostate cancer. However, the PREVAIL, AFFIRM and COU-AA studies demonstrati...
- Subjects :
- Oncology
Cancer Research
Chemotherapy
medicine.medical_specialty
Standard of care
business.industry
medicine.medical_treatment
Newly diagnosed
medicine.disease
humanities
Hormone-sensitive
Prostate cancer
Abiraterone
chemistry.chemical_compound
Docetaxel
chemistry
Internal medicine
medicine
Enzalutamide
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........9bced8885d7f542b3050b1e4f461be13
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.e17022